Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro

European Journal of Clinical Microbiology & Infectious Diseases

Volumn 11, Issue 12, 1992, Pages 1144-1155

  Snoeck, R ^a   Andrei, G ^a   Schols, D ^a   Balzarini, J ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; EMBRYO; FETUS LUNG; FIBROBLAST CULTURE; HOST CELL; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DRUG COMBINATIONS; DRUG SYNERGISM; HUMAN; SUPPORT, NON-U.S. GOV'T; VIRUS REPLICATION;

EID: 0027096096     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/BF01961133     Document Type: Article

References (54)

1. Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection
2. Pediatric cytomegalovirus infection
3. Cytomegalovirus infection in transplant patients
4. Treatment of CMV infections and disease in transplantation
5. Risk factors for cytomegalovirus infection after human marrow transplantation
6. Death in the AIDS patients: role of cytomegalovirus
7. Cytomegalovirus and the acquired immunodeficiency syndrome
8. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS
9. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men
10. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts
11. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia
12. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
13. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
14. Prevalence of resistance in patients receiving ganciclovir or serious cytomegalovirus infection
15. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients
16. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients
17. Pharmacokinetics, safety, and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients
18. Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS
19. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet)
20. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS
21. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
22. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient
23. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
24. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
25. A novel selective broad-spectrum anti-DNA virus agent
26. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines
27. Broad-spectrum anti-DNA virus and antiretrovirus activity of phosphonylmethoxyalkyl-purines and -pyrimidines
28. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine, a potent and selective inhibitor of human cytomegalovirus replication
29. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique
30. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus
31. Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro
32. Ribavirin antagonizes the effect of azidothymidine on HIV replication
33. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro
34. Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro
35. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro
36. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro
37. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo
38. Antiviral activity and mechanisms of action of ganciclovir
39. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex and cellular origin
40. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG)
41. A human cytomegalovirus mutant resistant to the nucleoside analog 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (BW B759U) induces reduced levels of BW B759U triphosphate
42. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs
43. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir
44. (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), a potent and selective inhibitor of cytomegalovirus infection in vitro and in vivo
45. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat CMV infection in vitro and in vivo
46. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice
47. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro
48. Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry
49. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleoside triphosphate pools of cultured human cells
50. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase
51. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells
52. Characteristics of cytomegalovirus
53. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro
54. Combinations of 3′-azido-3′-deoxythymidine (Zidovudine) and phosphonoformate (Foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro